FDA greenlights nine Lyrica generics
Nine companies, including Teva, Alembic and Amneal receive US FDA approval for generic versions of Pfizer’s blockbuster Lyrica.
Archives for July 23, 2019
DIA 2019
A hidden gem: Emerald device wirelessly detects clinical trial patients using radio signals and AI
MIT has developed an ‘invisible’ device that provides several benefits over traditional patient data collection methods, including improved biomarker development and the ability to detect changes in behavior – by monitoring patients wirelessly, and...
Parexel opens consulting subsidiary in Hong Kong
Parexel’s consulting subsidiary Health Advances opens in Hong Kong to provide business strategy as well as scientific and clinical expertise to customers in the region.
Consortium creates a ‘behavioral biomarker’ through AI models
The AI technology company BlackThorn joins a consortium to develop predictive models for neurobehavioral disorder clinical trial inclusion criteria.
Pfizer inks strategic collaboration with Syapse to analyze RWD, advance outcomes research
Syapse today announces a strategic collaboration with Pfizer through which it will generate insights from de-identified real-world data and advance oncology outcomes research.
Site consolidation: Meridian boosts US footprint in response to demand for ‘expanded relationships’
Meridian Clinical Research acquires Regional Clinical Research in a deal that will see its North American footprint expand to more than 20 investigative clinical trial sites.
Janssen applies to US and EU for subcutaneous Darzalex
Janssen aims to expand the label of delivery in the US and EU for its product, Darzalex, to include subcutaneous delivery through the use of Halozyme’s technology.